Current Clinical Trials

Therapeutic Area Condition Description
Bleeding Disorders
Hemophilia A An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. Learn More
Hemophilia B A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B Learn More
Hemophilia A & B A Study to Investigate the Pharmacokinetics, Efficacy, and Safety of rVIIa-FP (CSL 689) in Subjects With Hemophilia (A or B) and Inhibitors Learn More
Congenital Fibrinogen Deficiency An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency Completed
Von Willebrand Study of Voncento® in Subjects With Von Willebrand Disease Completed
Warfarin Reversal An Observational Study of the Risk of Thromboembolic Events Among Adult Patients Treated With KCENTRA® Compared With Plasma for Urgent Reversal of Vitamin K Antagonist Therapy in the Setting of Acute Major Bleeding Learn More
Cardiovascular Acute Coronary Syndrome  Study to investigate CSL112 in Subjects With Acute Coronary Syndrome Learn More
  Coronary Heart Disease Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults Learn More
Immunoglobulins Chronic Inflammatory Demyelinating Polyneuropathy Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Learn More
  Primary Immune Deficiency (PID) Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) Learn More
Primary Immune Deficiency (PID) Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Completed
Therapeutic Proteins Other Inflammatory or immune system disorders Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Learn More
Transplant Antibody-mediated kidney transplant rejection Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients Learn More